Patients who experience adverse ocular effects with bisphosphonates have a notably higher risk for osteonecrosis than those who do not experience such events, a large cohort study shows. Medscape Medical News
Uncategorized
2026 health trends: GLP-1s, wearable technology, food as medicine
This year’s top health trend will be the expanded use of GLP-1 receptor agonists to treat chronic disease, according to experts surveyed by the editors of U.S. News and World Report.Tied for second place was the growth of wearable technology with AI in…
Uncategorized
Consider eye movement during femtosecond-laser assisted LASIK
Eye movement during femtosecond laser-assisted LASIK shows variability, suggesting the need for careful consideration during surgical planning, according to a study published in Journal of Refractive Surgery.Soodabeh Darzi, PhD, and colleagues wrote th…
Uncategorized
Ellipsoid zone a clinically relevant endpoint in AMD, GA trials
ORLANDO — A study supported the ellipsoid zone loss as a meaningful biomarker that can be used to guide clinical trial design in age-related macular degeneration assessment, according to a speaker here.At the American Academy of Ophthalmology meeting, …
Uncategorized
Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S.
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, is launching its fifth annual fundraising challenge with Glaucoma Research Foundat…
Uncategorized
Samsung Bioepis beginnt mit der Vermarktung von BYOOVIZ®, einem Biosimilar zu Lucentis (Ranibizumab), in Europa
INCHEON, Korea–(BUSINESS WIRE)–Samsung Bioepis Co., Ltd. gab heute bekannt, dass das Unternehmen mit der direkten Vermarktung von BYOOVIZ®, einem Biosimilar zu Lucentis1 (Ranibizumab), in Europa begonnen hat. Samsung Bioepis hat daran gearbeitet, ein…